Phenotypes Associated with This Genotype

Genotype
MGI:6507865

• Allelic Composition: Igs2^{tm1(CAG-Met)Zsu}/Igs2⁺; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

endocrine/exocrine glands

endocrine/exocrine gland phenotype ( J:268934 )

N • mice do not show any obvious pathological changes in prostate tissues from birth to 20 months of age

increased prostate intraepithelial neoplasia incidence ( J:268934 )

• mice administered recombinant human hepatocyte growth factor at 6 months of age show lesions of typical low-grade prostatic intraepithelial neoplasia not seen in hepatocyte growth factor-administered wild-type mice

• however, hepatocyte growth factor-administered mice do not develop prostate carcinomas

reproductive system

increased prostate intraepithelial neoplasia incidence ( J:268934 )

• mice administered recombinant human hepatocyte growth factor at 6 months of age show lesions of typical low-grade prostatic intraepithelial neoplasia not seen in hepatocyte growth factor-administered wild-type mice

• however, hepatocyte growth factor-administered mice do not develop prostate carcinomas

neoplasm

increased prostate intraepithelial neoplasia incidence ( J:268934 )

• mice administered recombinant human hepatocyte growth factor at 6 months of age show lesions of typical low-grade prostatic intraepithelial neoplasia not seen in hepatocyte growth factor-administered wild-type mice

• however, hepatocyte growth factor-administered mice do not develop prostate carcinomas